Tenaya Therapeutics (TNYA) Gains from Sales and Divestitures (2021 - 2026)
Tenaya Therapeutics' quarterly Gains from Sales and Divestitures came in at $238593.0 in Q1 2026, down 19.17% year-on-year from $295191.0 in Q1 2025, and down 73.9% quarter-over-quarter from $914079.0 in Q4 2025.
Tenaya Therapeutics has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $238593.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 19.17% year-over-year to $238593.0; the trailing twelve-month figure through Mar 2026 stood at $238593.0 (down 19.17% YoY), and the FY2025 full-year result was $914079.0, up 32.07% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $238593.0, down from $914079.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $914079.0 in Q4 2025, with the low at $8311.0 in Q1 2023.
- Average Gains from Sales and Divestitures over 5 years is $333781.7, with a median of $254172.0 recorded in 2023.
- Year-over-year, Gains from Sales and Divestitures plunged 91.08% in 2022 and soared 3041.82% in 2024.
- Tracing TNYA's Gains from Sales and Divestitures over 5 years: stood at $8932.0 in 2022, then jumped by 2745.63% to $254172.0 in 2023, then soared by 172.29% to $692096.0 in 2024, then surged by 32.07% to $914079.0 in 2025, then slumped by 73.9% to $238593.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $238593.0 (Q1 2026), $914079.0 (Q4 2025), and $732036.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238,593.00 |
| Mar 31, 2026 | 238,593.00 |
| Dec 31, 2025 | 914,079.00 |
| Dec 31, 2025 | 914,079.00 |
| Sep 30, 2025 | 732,036.00 |
| Sep 30, 2025 | 732,036.00 |
| Jun 30, 2025 | 491,198.00 |
| Jun 30, 2025 | 491,198.00 |
| Mar 31, 2025 | 295,191.00 |
| Mar 31, 2025 | 295,191.00 |
| Dec 31, 2024 | 692,096.00 |
| Dec 31, 2024 | 692,096.00 |
| Sep 30, 2024 | 596,544.00 |
| Sep 30, 2024 | 596,544.00 |
| Jun 30, 2024 | 261,117.00 |
| Jun 30, 2024 | 261,117.00 |
| Mar 31, 2024 | 243,041.00 |
| Mar 31, 2024 | 243,041.00 |
| Dec 31, 2023 | 254,172.00 |
| Dec 31, 2023 | 254,172.00 |
| Sep 30, 2023 | 254,172.00 |
| Sep 30, 2023 | 254,172.00 |
| Jun 30, 2023 | 8,311.00 |
| Jun 30, 2023 | 8,311.00 |
| Mar 31, 2023 | 8,311.00 |
| Mar 31, 2023 | 8,311.00 |
| Dec 31, 2022 | 8,932.00 |
| Dec 31, 2022 | 8,932.00 |
| Sep 30, 2022 | 8,932.00 |
| Sep 30, 2022 | 8,932.00 |
| Sep 30, 2021 | 100,105.00 |
| Sep 30, 2021 | 100,105.00 |
| Jun 30, 2021 | 70,322.00 |
| Jun 30, 2021 | 70,322.00 |